Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 54,039,452
  • Shares Outstanding, K 213,620
  • Annual Sales, $ 11,449 M
  • Annual Income, $ 3,703 M
  • 36-Month Beta 0.81
  • Price/Sales 4.73
  • Price/Cash Flow 10.71
  • Price/Book 4.72

Price Performance

See More
Period Period Low Period High Performance
1-Month
246.12 +2.91%
on 05/24/17
281.22 -9.94%
on 04/27/17
-26.70 (-9.54%)
since 04/26/17
3-Month
246.12 +2.91%
on 05/24/17
298.00 -15.01%
on 03/03/17
-31.85 (-11.17%)
since 02/24/17
52-Week
205.43 +23.29%
on 06/27/16
307.33 -17.59%
on 08/02/16
-6.47 (-2.49%)
since 05/26/16

Most Recent Stories

More News
Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer

Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody....

MRK : 65.05 (+0.02%)
UNH : 177.41 (-0.36%)
BMY : 54.20 (-0.35%)
BIIB : 253.07 (+0.04%)
Biogen (BIIB) Down 9.5% Since Earnings Report: Can It Rebound?

BIIB reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BIIB : 253.07 (+0.04%)
Biogen's Fampyra Conditional Approval Converted to Standard

Biogen Inc. (BIIB) announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard...

IONS : 46.82 (+1.01%)
ABBV : 65.96 (-0.54%)
ACOR : 14.30 (-1.72%)
BIIB : 253.07 (+0.04%)
Biogen Acquires Remedy Pharmaceuticals' Late-Stage Drug CIRARA(TM)

Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving treatments to people affected by central nervous system diseases and injuries, today announced...

BIIB : 253.07 (+0.04%)
Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal

Quite a few deals were announced this week including by companies like Biogen (BIIB).

SGMO : 7.68 (-1.54%)
AKBA : 13.59 (-1.88%)
VRTX : 120.22 (+1.37%)
IONS : 46.82 (+1.01%)
REGN : 456.77 (+0.23%)
ALXN : 97.46 (-1.06%)
BIIB : 253.07 (+0.04%)
Biogen (BIIB) Buys Stroke Candidate Cirara for $120M

Biogen Inc. (BIIB) announced the acquisition of Remedy Pharmaceuticals' phase III candidate, Cirara for the treatment of large hemispheric stroke (LHI).

AKTX : 6.71 (+0.30%)
IONS : 46.82 (+1.01%)
BMY : 54.20 (-0.35%)
BIIB : 253.07 (+0.04%)
Biotech Stocks Under Scanner -- BioCryst Pharma, Biogen, Celldex Therapeutics, and Concordia

On Monday, May 15, 2017, the NASDAQ Composite ended the trading session at 6,149.67, up 0.46%; the Dow Jones Industrial Average edged 0.41% higher, to finish at 20,981.94; and the S&P 500 closed at 2,402.32,...

CLDX : 3.12 (+0.65%)
CXRX : 1.29 (unch)
BCRX : 5.91 (-12.18%)
BIIB : 253.07 (+0.04%)
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 1.43%

Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $257.02 to a high of $262.30. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $259.99...

BIIB : 253.07 (+0.04%)
4 Drug Stocks Poised to Beat this Earnings Season

M&A and licensing deals as well as drug pricing issues are expected to remain in focus in 2017.

ENDP : 13.10 (+1.63%)
JNJ : 126.91 (-0.49%)
IMDZ : 8.00 (-1.23%)
LLY : 78.10 (-0.31%)
IONS : 46.82 (+1.01%)
EDIT : 16.08 (-1.41%)
GILD : 64.51 (-0.08%)
BIIB : 253.07 (+0.04%)
The Zacks Analyst Blog Highlights: Exxon Mobil, JPMorgan, Union Pacific, Biogen and Becton Dickinson

The Zacks Analyst Blog Highlights: Exxon Mobil, JPMorgan, Union Pacific, Biogen and Becton Dickinson

JPM : 85.44 (+0.11%)
UNP : 110.61 (+0.83%)
XOM : 81.60 (-0.18%)
BDX : 186.17 (-0.32%)
BIIB : 253.07 (+0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Support & Resistance

2nd Resistance Point 255.59
1st Resistance Point 254.28
Last Price 253.07
1st Support Level 251.83
2nd Support Level 250.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.